Cancer in Acromegaly

Jenkins, Paul J.

doi:10.1016/s1043-2760(98)00093-9

Cited by 11 publications

(5 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bergmann et al described an increase in the expression of IGF-1 and IGF-1R in pancreatic cancer tissues in 1995 [16]. As a side note, Acromegaly, where high concentrations of growth hormone also lead to an increased production of insulin-like growth factor-I, has also been associated with an elevated risk of colorectal and breast cancer [18]. As a side note, Acromegaly, where high concentrations of growth hormone also lead to an increased production of insulin-like growth factor-I, has also been associated with an elevated risk of colorectal and breast cancer [18].…”

Section: The Igf System and Cancermentioning

confidence: 99%

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

Rieder

Michalski²,

Friess³

et al. 2011

ACAMC

View full text Add to dashboard Cite

Insulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In pancreatic cancer, IGF-1 and its receptor are constitutively overexpressed. Mammalian target of rapamycin (mTOR) is the main mediator of mitogenic stimuli transduced by PI3K/Akt. Interestingly, inhibition of mTOR activates PI3K/Akt by up-regulating IGF-1R signaling. Several targeted agents have been developed to inhibit the activity of IGF-1 or to block IGF-1R. These pharmaceuticals may offer additional ways of stimulating apoptosis in neoplastic cells. Yet, there are difficulties in targeting this pathway: The ideal anti-cancer drug target is expressed only in cancer cells; however, IGF-1 and its receptor IGF-1R are ubiquitously expressed throughout the body. Moreover, when using antibodies against IGF-1R, the structurally similar insulin receptor might also be blocked, leading to hyperglycemia as a severe side effect. There are currently several phase I/II trials investigating IGF-1 and its receptor as a drug target in various kinds of cancer. Specifically, therapeutic effects on pancreatic cancer by combining a humanized monoclonal antibody against IGF-1R with other chemotherapeutics are being investigated. To improve the clinical outcome of mTOR inhibitors such as everolimus, it has been suggested to use combination therapies of mTOR inhibitors and IGF-1/IGF-1R inhibitors. In theory, this would counterbalance the feedback effects of mTOR inhibition on IGF-1 signaling. In conclusion, IGF-1 and its receptor are promising new drug targets in cancer therapy. Combination therapies of IGF-1/IGF-1R inhibitors and mTOR inhibitors could improve the clinical outcome.

show abstract

Section: The Igf System and Cancermentioning

confidence: 99%

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

Rieder

Michalski²,

Friess³

et al. 2011

ACAMC

View full text Add to dashboard Cite

show abstract

“…Indeed, GH is now said to be the most widely abused performance-enhancing agent. This is of concern, not only because of the undesirable effects on the ethos of sport and fair competition, but also because the long-term administration of high dose GH is potentially dangerous [10]. GH is banned by The International Olympic Committee and World Anti Doping Agency.…”

Section: Introductionmentioning

confidence: 99%

Detection of growth hormone abuse in sport

Powrie

Bassett

Rosén

et al. 2007

Growth Hormone & IGF Research

134

140

View full text Add to dashboard Cite

“…Data from an Italian group show that active acromegaly in women is strongly associated with higher visceral adiposity dysfunction, insulin resistance, and DM [22]. That elevated GH, IGF-1, and insulin levels in acromegaly are potentially involved in tumour promotion and progression has been a concern for several decades [9,23]. A variety of cancers, particularly colorectal, breast, and thyroid cancers, and perhaps haematological malignancies, were reported for a number of regions worldwide [24][25][26].…”

Section: Discussionmentioning

confidence: 99%

Wpływ cukrzycy na przeżycie pacjentów z akromegalią

Chiou

Chen

Liu

et al. 2016

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up. Materials and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, 86.9%, and 84.7% for the DM group, respectively, and 96.5%, 96.5%, and 96.5% for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit. Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy.

show abstract

Cancer in Acromegaly

Cited by 11 publications

References 70 publications

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

Detection of growth hormone abuse in sport

Wpływ cukrzycy na przeżycie pacjentów z akromegalią

Contact Info

Product

Resources

About